Abstract |
Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID ( thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID ( vincristine, idarubicin, dexamethasone) or with VRID ( vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.
|
Authors | Britta Auel, Hartmut Goldschmidt, Thomas Geer, Thomas M Moehler, Uwe Platzbecker, Ralph Naumann, Igor Blau, Mathias Hänel, Wolfgang Knauf, Holger Nückel, Hans-Jürgen Salwender, Christof Scheid, Katja Weisel, Marcus Gorschlüter, Axel Glasmacher, Ingo G H Schmidt-Wolf, German Refractory Myeloma Study Group |
Journal | Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
(Indian J Hematol Blood Transfus)
Vol. 28
Issue 2
Pg. 67-76
(Jun 2012)
ISSN: 0971-4502 [Print] India |
PMID | 23730012
(Publication Type: Journal Article)
|